Clinical trial
Study of MDX-010 in Stage IV Breast Cancer
NCT00083278 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00083278 |
|---|---|
| Title | Study of MDX-010 in Stage IV Breast Cancer |
| Official title | A Phase II Study of MDX-010 in Patients With Stage IV Adenocarcinoma of the Breast |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Adenocarcinoma |
| Intervention type | Drug |
| Interventions | MDX-010 |
| Enrollment | 33 |
| Start date | May 1, 2003 |
| Completion | Feb 1, 2006 |
| First posted | May 20, 2004 |
| Last update posted | Apr 27, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: